Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Ives Health Co. - IVEH -- Ignore unavailable to you. Want to Upgrade?

To: peter michaelson who wrote (7)	2/27/2001 10:27:58 PM
From: peter michaelson	Read Replies (1) \| Respond to of 40

IVEH scheduled some for-pay internet radio presentations...pump, pump, pump...new PR still skirts around the age of the study and the non-proprietary nature of the product. CLAREMORE, Okla.--(BW HealthWire)--Feb. 21, 2001--Ives Health Company (OTCBB:IVEH - news) announced today that the Company's Founder and Chairman of the Board, Keith Ives, will be interviewed by Wisdom Radio, RadioNet and MarketMarquee this week. Keith Ives stated: ``We are beginning to receive more attention from the media as T-Factor(TM) gains momentum. The response from the HIV community has been much greater than we reasonably expected and we believe T-Factor(TM) is the only naturalpath remedy on the market capable of increasing T-Cell counts dramatically. We expect this trend to continue.'' The schedule is as follows: Wed., Feb 21 MarketMarquee (not available live) Fri., Feb 23 RadioNet Internet Talk Radio (not available live) Sat., Feb 24 Wisdom Radio 12:00 noon CST Check your local radio listings for availability in your area (also available through webcasting at wisdomradio.com). Wisdom Radio will have a listener call-in segment during the interview in which the public will be able to ask questions of Keith Ives. Members of the public can call 1-800/655-2112 during the interview for more information. RadioNet will accept suggested questions from the public that are submitted prior to the interview. Please e-mail suggestions to radionet@radionet.com. Links to the archived interviews will be provided on the Company's website at iveshealth.com. The results of the Java Project, the revolutionary study confirming the potency of T-Factor, are also posted on the Company's website. According to many popular sources, over 250 million people are infected by HIV worldwide. About the Java Project and T-Factor(TM) The Java Project was a landmark AIDS study carried out by Dr. Slayton-Bedeen, along with the World Health Organization in Jakarta and Bangkok. The project found that new hormonal inhibitors of the Human Immunodeficiency Virus (HIV), like T-Factor(TM), might initiate profound and sustained suppression of HIV replication. The T-Factor(TM) formula was administered to 186 HIV-positive patients of Asian descent with elevated HIV RNA and decreased CD-4 counts, over a period of 24 weeks. The results were dramatic, with over 80% of patients experiencing documented decreases in HIV RNA and enhanced CD-4 counts after 24 weeks. The T-Factor(TM) formula, acquired by Ives Health Company in 1998, is all-natural, has virtually no side effects, and is readily available over the Internet at iveshealth.com. T-Factor(TM) currently costs less than $50.00 per month, versus as much as $2,400.00 per month for current HIV drug therapies. According to Ives Health, T-Factor differentiates itself from other HIV drugs under development, like the Gilead Sciences (Nasdaq:GILD - news) product, because T-Factor is all-natural with virtually no side effects, yet has been proven effective in over 80% of tested patients. T-Factor is currently available on the market. New studies are ongoing in the United States and recently began in Europe. Findings will be released as the data is reported and validated. T-Factor(TM), not a cure for HIV, is intended to extend the lives of those afflicted with the virus.